CAMBRIDGE, Mass.--(BUSINESS WIRE)--TransMolecular, Inc., a biotechnology company focused on targeted therapies for cancer, today announced the presentation of an imaging and pharmacokinetic analysis of intravenous 131I-TM601 in patients with primary malignant glioma or solid tumor metastases. The abstract was discussed in an oral presentation at the Society for Nuclear Medicine’s 55th Annual Meeting on June 16, 2008 by investigators at Northwestern Memorial Hospital and Northwestern University Feinberg School of Medicine.
